Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.
Saved in:
| Title: | Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. |
|---|---|
| Authors: | Drilon A; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States., Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Camidge DR; Anschutz Medical Campus, University of Colorado, Aurora, CO, United States., Nagasaka M; School of Medicine, University of California, Irvine, Orange, CA, United States., Besse B; Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France., Solomon B; Peter MacCallum Cancer Centre, Melbourne, Australia., Goto K; National Cancer Center Hospital East, Kashiwa, Japan., Wolf J; Centrum für Integrierte Onkologie-Uniklinik Köln, Köln, Germany., Popat S; The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom., Felip E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Yang N; The Second People's Hospital of Hunan Province, Hunan, China., de Langen AJ; Netherlands Cancer Institute, Amsterdam, The Netherlands., Lu S; Department of Oncology, Shanghai Chest Hospital, Shanghai, China., Velcheti V; Mayo Clinic, Jacksonville, FL,United States., Lin AL; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States., Calvet CY; Bristol Myers Squibb, Princeton, NJ, United States., Li L; Bristol Myers Squibb, Princeton, NJ, United States., Tschaika M; Bristol Myers Squibb, Princeton, NJ, United States., Afsar S; Bristol Myers Squibb, Princeton, NJ, United States., Yang H; Bristol Myers Squibb, Princeton, NJ, United States., Lin JJ; Harvard Medical School, Mass General Brigham Cancer Institute, Boston, MA, United States. |
| Source: | The oncologist [Oncologist] 2026 May 08; Vol. 31 (6). |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyag137 |
